Biosimilar Newsletter Archive

41. 04.08.21 -- Biosimilar Education Across Europe: The Right Message 4/8/2021
    04/08/21 Biosimilar Development Newsletter
42. 04.07.21 -- Listen Now: Antiviral Conjugates, Peptides, Biopharma Funding Success 4/7/2021
    04/07/21 Biosimilar Development Newsletter
43. 04.01.21 -- Subcutaneous Infliximab Across Indications: U.S. Impact 4/1/2021
    04/01/21 Biosimilar Development Newsletter
44. 03.29.21 -- Scalable Manufacturing Of Adeno Viral Vector For Gene Therapy 3/29/2021

    03/29/21 Biosimilar Development Newsletter

45. 03.25.21 -- Defining Subcutaneous Infliximab's U.S. Potential 3/25/2021
    03/25/21 Biosimilar Development Newsletter
46. 03.18.21 -- Biosimilar Regulatory And Legislative Actions Set Tone For 2021 3/18/2021
    03/18/21 Biosimilar Development Newsletter
47. 03.11.21 -- The Past, Present, And Future Of Biosimilar Manufacturing 3/11/2021
    03/11/21 Biosimilar Development Newsletter
48. 03.10.21 -- Standing At The Intersection Of Advanced Process And Digital Technologies 3/10/2021

    03/10/21 Biosimilar Development Newsletter

49. 03.09.21 -- Listen Now - The FDA's Progressive Appeal, AI And The Human Genome, And More 3/9/2021
    03/09/21 Biosimilar Development Newsletter
50. 03.08.21 -- Biotech Founders Share Insights On FDA, CMC, And GMP 3/8/2021

    03/08/21 Biosimilar Development Newsletter